Education
About Us
Working with TipRanks
Follow Us
Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
RESEARCH TOOLSreports
ATX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.43
Previous CloseN/A
Volume274.48K
Average Volume (3M)9.81M
Market Cap
$110.77M
Enterprise ValueAU$106.06M
Total Cash (Recent Filing)$4.56M
Total Debt (Recent Filing)AU$54.99K
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding388,672,670
10 Day Avg. Volume7,328,490
30 Day Avg. Volume9,811,088
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)5.66
Price to Sales (P/S)0.00
P/FCF Ratio-40.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Amplia Therapeutics News
PremiumCompany Announcements
Amplia Therapeutics Initiates Trading Halt for Capital Raising
PremiumCompany Announcements
Amplia Therapeutics Reports Positive Results in Pancreatic Cancer Trial
PremiumCompany Announcements
Amplia Therapeutics Issues New Shares to Bolster Capital
PremiumCompany Announcements
Amplia Therapeutics Announces Date for Annual General MeetingPremiumCompany Announcements
Amplia Therapeutics Reports Promising Results in Pancreatic Cancer TrialPremiumCompany Announcements
Amplia Therapeutics Announces Change in Substantial Holder Interests
Options Prices
Currently, No data available
---
Ownership Overview
4.33% Insiders
―
Mutual Funds
― Other Institutional Investors
95.67% Public Companies and
Individual Investors
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.42 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is $110.77M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 27, 2025 which is in 129 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on May 30, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 388,672,670 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.961%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
Amplia Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ATX Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
412.19%
12-Months-Change
Fundamentals
Return on Equity
-41.60%
Trailing 12-Months
Asset Growth
47.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Ltd. (ATX) is a biotechnology company specializing in the development of targeted therapies for cancer and fibrotic diseases. The company focuses on advancing its proprietary drug candidates through clinical trials, aiming to address unmet medical needs in oncology and fibrosis treatment. With a commitment to innovative research, Amplia Therapeutics leverages its expertise in small molecule drugs to create effective therapeutic solutions.
Technical Analysis
Immutep Ltd
―
Cynata Therapeutics Limited
―
Race Oncology Ltd.
―
Proteomics International Laboratories Ltd.
―